Oncology Simulation Model: A Comprehensive and Innovative Approach to Estimate and Project Prevalence and Survival in Oncology

References

• Kantarjian H, O’Brien S, Cortes J, et al. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer. 2008;113(7 Suppl):1933–1952. doi:10.1002/cncr.23655
   PubMed Web of Science ®Google Scholar
• Yang R, Zhou Y, Wang Y, Du C, Wu Y. Trends in cancer incidence and mortality rates in the United States from 1975 to 2016. Ann Transl Med. 2020;8(24):1671. doi:10.21037/atm-20-7841
   Web of Science ®Google Scholar
• Li S, Peng Y, Weinhandl ED, et al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol. 2012;4:87–93. doi:10.2147/CLEP.S28339
   PubMedGoogle Scholar
• Rassen JA, Bartels DB, Schneeweiss S, Patrick AR, Murk W. Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases. Clin Epidemiol. 2019;11:1–15. doi:10.2147/CLEP.S181242
   PubMed Web of Science ®Google Scholar
• National Cancer Institute DoCCPS. Cancer prevalence statistics: approaches to estimation using cancer registry data. National Cancer Institute, Division of Cancer Control & Population Sciences. Available from: https://surveillance.cancer.gov/prevalence/approaches.html. Accessed September 18, 2021.
   Google Scholar
• Informatica ISdSSI. MIAMOD and PIAMOD methods and software for estimating incidence and prevalence from population-based cancer registries data; 2021. Available from: http://www.eurocare.it/MiamodPiamod/tabid/60/Default.aspx. Accessed June 16, 2021.
   Google Scholar
• Lancaster V, Bloudek L. PCN76 systematic literature review of budget impact models in oncology. Value Health. 2021;24:S33. doi:10.1016/j.jval.2021.04.168
   Google Scholar
• Roth JA, Goulart BH, Ravelo A, Kolkey H, Ramsey SD. Survival gains from first-line systemic therapy in metastatic non-small cell lung cancer in the U.S, 1990–2015: progress and opportunities. Oncologist. 2017;22(3):304–310. doi:10.1634/theoncologist.2016-0253
   Web of Science ®Google Scholar
• De Angelis R, Tavilla A, Verdecchia A, et al. Breast cancer survivors in the United States: geographic variability and time trends, 2005–2015. Cancer. 2009;115(9):1954–1966. doi:10.1002/cncr.24217
   Web of Science ®Google Scholar
• Verdecchia A, De Angelis G, Capocaccia R. Estimation and projections of cancer prevalence from cancer registry data. Stat Med. 2002;21(22):3511–3526. doi:10.1002/sim.1304
   Web of Science ®Google Scholar
• Simonetti A, Gigli A, Capocaccia R, Mariotto A. Estimating complete prevalence of cancers diagnosed in childhood. Stat Med. 2008;27(7):990–1007. doi:10.1002/sim.3010
   Web of Science ®Google Scholar
• Mariotto AB, Yabroff KR, Feuer EJ, De Angelis R, Brown M. Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000–2020. Cancer Causes Control. 2006;17(10):1215–1226. doi:10.1007/s10552-006-0072-0
   Web of Science ®Google Scholar
• Sarfaty M, Hall PS, Chan KKW, et al. Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer. Eur Urol. 2018;74(1):57–62. doi:10.1016/j.eururo.2018.03.006
   PubMed Web of Science ®Google Scholar
• Slater RL, Lai Y, Zhong Y, et al. The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. J Med Econ. 2020;23(9):967–977. doi:10.1080/13696998.2020.1770261
   PubMed Web of Science ®Google Scholar
• Hepp Z, Shah SN, Smoyer K, Vadagam P. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis. J Manag Care Spec Pharm. 2021;27(2):240–255. doi:10.18553/jmcp.2020.20285
   PubMed Web of Science ®Google Scholar
• Kaseb H, Aeddula NR. Bladder Cancer. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536923/. Accessed August 1 2022.
   Google Scholar
• National Comprehensive Cancer Network NCCN. NCCN clinical practice guidelines in oncology (NCCN guidelines). Bladder Cancer; 2022. Available from: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed August 1, 2022.
   Google Scholar
• Wirtz H, Hepp Z, McKay C, et al. PCN118 Estimated Prevalence of Treated Locally Advanced or Metastatic Urothelial Carcinoma in Canada Using Simulation Modeling. Value Health. 2021;24:S41. doi:10.1016/j.jval.2021.04.210
   Web of Science ®Google Scholar
• Schwartz NRM, DeBusk K, Bloudek L, et al. Estimation of the Prevalence of HER2+ metastatic breast cancer in the United States. J Manag Care Spec Pharm. 2021;27(10–bSuppl):S1–S119 doi:10.18553/jmcp.2021.27.10-b.s1
   Google Scholar
• Phillips T, Migliaccio-Walle K, Yu KS, et al. An oncology simulation model to estimate 10-year progression-free survival and stem cell transplantation for frontline, stage III or IV classical Hodgkin lymphoma based on the 5-year update of the ECHELON-1 trial: a United States perspective. Blood. 2021;138(Supplement 1):2440. doi:10.1182/blood-2021-147308
   Web of Science ®Google Scholar
• Burke JM, Yu KS, Mordi U, et al. An oncology simulation model to estimate 10-year progression-free survival and overall survival based on the 5-year update from the ECHELON-2 trial in frontline patients with peripheral T-cell lymphoma: a United States perspective. Blood. 2021;138:2466. doi:10.1182/blood-2021-148004
   Web of Science ®Google Scholar
• Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. International Agency for Research on Cancer; 2020. Available from: https://gco.iarc.fr/today. Accessed July 24, 2021.
   Google Scholar
• Ghatalia P, Zibelman M, Geynisman DM, Plimack E. Approved checkpoint inhibitors in bladder cancer: which drug should be used when? Ther Adv Med Oncol. 2018;10:1758835918788310. doi:10.1177/1758835918788310
   Web of Science ®Google Scholar
• National Cancer Institute. Surveillance, epidemiology, and end results program. Cancer stat facts: bladder cancer. Available from: https://seer.cancer.gov/statfacts/html/urinb.html. Accessed May 2, 2020.
   Google Scholar
• Flannery K, Boyd M, Black-Shinn J, Robert N, Kamat AM. Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study. Future Oncol. 2019;15(12):1323–1334. doi:10.2217/fon-2018-0654
   Web of Science ®Google Scholar
• Morgans A, Galsky MD, Hepp Z, et al. 704P Treatment patterns among patients with advanced urothelial carcinoma (aUC) in the USA. Ann Oncol. 2021;32:S714–S715. doi:10.1016/j.annonc.2021.08.100
   Web of Science ®Google Scholar
• Veeratterapillay R, Heer R, Johnson MI, Persad R, Bach C. High-risk non-muscle-invasive bladder cancer—therapy options during intravesical BCG shortage. Curr Urol Rep. 2016;17(9):68. doi:10.1007/s11934-016-0625-z
   Web of Science ®Google Scholar
• Yafi FA, Aprikian AG, Chin JL, et al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int. 2011;108(4):539–545. doi:10.1111/j.1464-410X.2010.09912.x
   Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2001;19(3):666–675. doi:10.1200/JCO.2001.19.3.666
   PubMed Web of Science ®Google Scholar